XML 24 R7.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2019   67,468,022      
Beginning balance at Dec. 31, 2019 $ 205,237 $ 6 $ 340,929 $ (285) $ (135,413)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (33,477)       (33,477)
Issuance of common stock from public offering, net of issuance costs (in shares)   1,931,206      
Issuance of common stock from public offering, net of issuance costs $ 107,915 $ 1 107,914    
Issuance of common stock to directors (in shares)   7,942      
Vesting of restricted stock units (in shares)   270,609      
Exercise of stock options (in shares) 1,001,411 1,001,411      
Exercise of stock options $ 6,376   6,376    
Stock-based compensation expense 15,279   15,279    
Other comprehensive loss (4,725)     (4,725)  
Ending balance (in shares) at Dec. 31, 2020   70,679,190      
Ending balance at Dec. 31, 2020 296,605 $ 7 470,498 (5,010) (168,890)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss $ (88,641)       (88,641)
Issuance of common stock to directors (in shares)   4,950      
Vesting of restricted stock units (in shares)   354,130      
Exercise of stock options (in shares) 423,824 423,824      
Exercise of stock options $ 2,786   2,786    
Stock-based compensation expense 23,844   23,844    
Other comprehensive loss (677)     (677)  
Ending balance (in shares) at Dec. 31, 2021   71,462,094      
Ending balance at Dec. 31, 2021 233,917 $ 7 497,128 (5,687) (257,531)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss $ (150,920)       (150,920)
Issuance of common stock to directors (in shares)   14,928      
Vesting of restricted stock units (in shares)   403,648      
Exercise of stock options (in shares) 937,217 937,217      
Exercise of stock options $ 25,432   25,432    
Stock-based compensation expense 38,830   38,830    
Other comprehensive loss (1,559)     (1,559)  
Ending balance (in shares) at Dec. 31, 2022   72,817,887      
Ending balance at Dec. 31, 2022 $ 145,700 $ 7 $ 561,390 $ (7,246) $ (408,451)